Jason Gerberry
Stock Analyst at B of A Securities
(3.80)
# 716
Out of 4,748 analysts
157
Total ratings
56.76%
Success rate
6.33%
Average return
Main Sectors:
Stocks Rated by Jason Gerberry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMVT Immunovant | Maintains: Buy | $48 → $45 | $21.79 | +106.52% | 4 | Jan 15, 2025 | |
| CPRX Catalyst Pharmaceuticals | Reiterates: Buy | $30 | $23.96 | +25.21% | 2 | Jan 9, 2025 | |
| EXEL Exelixis | Downgrades: Neutral | $35 → $39 | $32.96 | +18.33% | 2 | Dec 17, 2024 | |
| BLUE bluebird bio | Downgrades: Neutral | $60 → $10 | $7.55 | +32.45% | 8 | Nov 15, 2024 | |
| ACLX Arcellx | Maintains: Buy | $84 → $100 | $64.58 | +54.85% | 4 | Nov 6, 2024 | |
| BHVN Biohaven | Maintains: Buy | $52 → $62 | $37.73 | +64.33% | 1 | Sep 24, 2024 | |
| RLAY Relay Therapeutics | Maintains: Buy | $20 → $24 | $4.48 | +435.71% | 1 | Sep 10, 2024 | |
| PROK ProKidney | Maintains: Neutral | $4 → $3 | $1.60 | +87.50% | 3 | Sep 4, 2024 | |
| PCVX Vaxcyte | Maintains: Buy | $101 → $140 | $88.67 | +57.89% | 8 | Sep 4, 2024 | |
| AXSM Axsome Therapeutics | Upgrades: Buy | $95 → $106 | $105.14 | +0.82% | 4 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $68 | $32.88 | +106.81% | 5 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $22.15 | -9.71% | 3 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $21 | $18.54 | +13.27% | 12 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $82 → $91 | $127.02 | -28.36% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $41 → $31 | $23.17 | +33.79% | 6 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $11 | $0.18 | +5,934.01% | 3 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $29 | $31.56 | -8.11% | 9 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $37 | $19.95 | +85.46% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $56 | $40.19 | +39.34% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $38.82 | -22.72% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $63 | $36.42 | +72.98% | 1 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 | $11.33 | -20.56% | 2 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $204 → $217 | $124.27 | +74.62% | 5 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $4 → $2 | $0.48 | +316.67% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $450 → $500 | $804.08 | -37.82% | 15 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $72 → $48 | $4.99 | +861.92% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 | $1.84 | +389.13% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $37 → $25 | $15.84 | +57.83% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $5 | $1.73 | +189.00% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $27 | $7.47 | +261.45% | 4 | Mar 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $20 | $1.22 | +1,539.34% | 1 | Jul 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $10 | $0.72 | +1,290.63% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $95 | $175.26 | -45.79% | 10 | May 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $59.05 | +1.61% | 7 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $37 | $26.62 | +38.99% | 4 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $90 | $98.28 | -8.42% | 11 | Oct 17, 2019 |
Immunovant
Jan 15, 2025
Maintains: Buy
Price Target: $48 → $45
Current: $21.79
Upside: +106.52%
Catalyst Pharmaceuticals
Jan 9, 2025
Reiterates: Buy
Price Target: $30
Current: $23.96
Upside: +25.21%
Exelixis
Dec 17, 2024
Downgrades: Neutral
Price Target: $35 → $39
Current: $32.96
Upside: +18.33%
bluebird bio
Nov 15, 2024
Downgrades: Neutral
Price Target: $60 → $10
Current: $7.55
Upside: +32.45%
Arcellx
Nov 6, 2024
Maintains: Buy
Price Target: $84 → $100
Current: $64.58
Upside: +54.85%
Biohaven
Sep 24, 2024
Maintains: Buy
Price Target: $52 → $62
Current: $37.73
Upside: +64.33%
Relay Therapeutics
Sep 10, 2024
Maintains: Buy
Price Target: $20 → $24
Current: $4.48
Upside: +435.71%
ProKidney
Sep 4, 2024
Maintains: Neutral
Price Target: $4 → $3
Current: $1.60
Upside: +87.50%
Vaxcyte
Sep 4, 2024
Maintains: Buy
Price Target: $101 → $140
Current: $88.67
Upside: +57.89%
Axsome Therapeutics
Aug 6, 2024
Upgrades: Buy
Price Target: $95 → $106
Current: $105.14
Upside: +0.82%
Jul 23, 2024
Maintains: Buy
Price Target: $67 → $68
Current: $32.88
Upside: +106.81%
Jun 11, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $22.15
Upside: -9.71%
May 30, 2024
Maintains: Buy
Price Target: $18 → $21
Current: $18.54
Upside: +13.27%
Apr 17, 2024
Maintains: Buy
Price Target: $82 → $91
Current: $127.02
Upside: -28.36%
Apr 1, 2024
Downgrades: Underperform
Price Target: $41 → $31
Current: $23.17
Upside: +33.79%
Mar 25, 2024
Maintains: Buy
Price Target: $12 → $11
Current: $0.18
Upside: +5,934.01%
Jan 2, 2024
Maintains: Neutral
Price Target: $27 → $29
Current: $31.56
Upside: -8.11%
Jan 2, 2024
Maintains: Buy
Price Target: $29 → $37
Current: $19.95
Upside: +85.46%
Jan 2, 2024
Maintains: Buy
Price Target: $52 → $56
Current: $40.19
Upside: +39.34%
Jan 2, 2024
Downgrades: Underperform
Price Target: $30
Current: $38.82
Upside: -22.72%
Nov 17, 2023
Initiates: Neutral
Price Target: $63
Current: $36.42
Upside: +72.98%
Oct 23, 2023
Downgrades: Underperform
Price Target: $9
Current: $11.33
Upside: -20.56%
Aug 10, 2023
Maintains: Buy
Price Target: $204 → $217
Current: $124.27
Upside: +74.62%
Aug 8, 2023
Downgrades: Underperform
Price Target: $4 → $2
Current: $0.48
Upside: +316.67%
May 24, 2023
Maintains: Buy
Price Target: $450 → $500
Current: $804.08
Upside: -37.82%
May 16, 2023
Maintains: Underperform
Price Target: $72 → $48
Current: $4.99
Upside: +861.92%
Dec 12, 2022
Downgrades: Underperform
Price Target: $9
Current: $1.84
Upside: +389.13%
Oct 14, 2022
Downgrades: Underperform
Price Target: $37 → $25
Current: $15.84
Upside: +57.83%
Dec 2, 2021
Downgrades: Underperform
Price Target: $45 → $5
Current: $1.73
Upside: +189.00%
Mar 24, 2021
Downgrades: Underperform
Price Target: $27
Current: $7.47
Upside: +261.45%
Jul 16, 2020
Initiates: Neutral
Price Target: $20
Current: $1.22
Upside: +1,539.34%
Jul 15, 2020
Downgrades: Neutral
Price Target: $17 → $10
Current: $0.72
Upside: +1,290.63%
May 18, 2020
Reinstates: Neutral
Price Target: $95
Current: $175.26
Upside: -45.79%
Oct 17, 2019
Reinstates: Buy
Price Target: $60
Current: $59.05
Upside: +1.61%
Oct 17, 2019
Reinstates: Neutral
Price Target: $37
Current: $26.62
Upside: +38.99%
Oct 17, 2019
Reinstates: Neutral
Price Target: $90
Current: $98.28
Upside: -8.42%